NCT04385589View on ClinicalTrials.gov

Dapagliflozin in Diabetic Patients (Type 2) With Decompensated Heart Failure

PHASE4CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

May 1, 2020

Primary Completion Date

December 15, 2020

Study Completion Date

December 20, 2020

Conditions
Heart Failure
Interventions
DRUG

Dapagliflozin

Patient will receive oral Dapagliflozin then monitoring of its efficacy on heart failure symptoms and outcome.

DRUG

insulin

insulin

Trial Locations (1)

71515

Assiut University, Aswān

All Listed Sponsors
lead

Assiut University

OTHER

NCT04385589 - Dapagliflozin in Diabetic Patients (Type 2) With Decompensated Heart Failure | Biotech Hunter | Biotech Hunter